Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 3, 2007 - Issue 4
Submit an article Journal homepage
733
Views
100
CrossRef citations to date
0
Altmetric
Review

Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans

Susan Hurst Senior Principal Scientist, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
,
Cho-Ming Loi Associate Research Fellow, Pfi zer Global Research and Development, Department of Pharmacokinetics, Dynamics and Metabolism, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
,
Joanne Brodfuehrer Senior Director, Pfi zer Global Research and Development, Department of Pharmaceutical Sciences, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
&
Ayman El-Kattan Senior Principal Scientist, Pfi zer Global Research and Development, Department of Pharmacokinetics, Dynamics and Metabolism, 2800 Plymouth Road, Ann Arbor, MI 48105, USA +1 734 622 2261; +1 734 622 4349; [email protected]@yahoo.com
Pages 469-489 | Published online: 19 Oct 2007

Bibliography

  • THOMAS VH, BHATTACHAR S, HITCHINGHAM L et al.: The road map to oral bioavailability: an industrial perspective. Expert Opin. Drug Metab. Toxicol. (2006) 2(4):591-608.
  • ABRAHAMSSON B, LENNERNAS H: Application of the biopharmaceutic classification system now and in the future. In: Drug Bioavailability, Estimation of Solubility, Permeability, Absorption, and Bioavailability. Waterbeemd HVD, Lennernas H, Artursson P (Eds), Wiley-VCH, New York, USA (2005):495-531.
  • LIU G, FRANSSEN E, FITCH MI, WARNER E: Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. (1997) 15(1):110-115.
  • PFEIFFER P, MORTENSEN JP, BJERREGAARD B et al.: Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur. J. Cancer (2006) 42(16):2738-2743.
  • TOUTAIN PL, BOUSQUET-MELOU A: Bioavailability and its assessment. J. Vet. Pharmacol. Ther. (2004) 27(6):455-466.
  • HELLRIEGEL ET, BJORNSSON TD, HAUCK WW: Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. (1996) 60(6):601-607.
  • BAILEY DG, KREEFT JH, MUNOZ C, FREEMAN DJ, BEND JR: Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′-dihydroxybergamottin in humans. Clin. Pharmacol. Ther. (1998) 64(3):248-256.
  • BARDELMEIJER HA, VAN TELLINGEN O, SCHELLENS JH, BEIJNEN JH: The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Invest. N. Drugs (2000) 18(3):231-241.
  • CAO X, GIBBS ST, FANG L et al.: Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. (2006) 23(8):1675-1686.
  • LIN JH: Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. (1995) 23(10):1008-1021.
  • BAGGOT JD: Clinical pharmacokinetics in veterinary medicine. Clin. Pharmacokinet. (1992) 22(4):254-273.
  • MARTIGNONI M, GROOTHUIS GM, DE KANTER R: Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. (2006) 2(6):875-894.
  • ROWLAND M, TOZER T: Clinical Pharmacokinetics. Lippincott Williams & Wilkins, Philadelphia, USA (1995).
  • KWON Y: Handbook of Essential Pharmacokinetics, Pharmacodynamics, and Drug Metabolism for Industrial Scientists. Kluwer Academic/Plenium Publishers, New York, USA (2001).
  • OBACH RS: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half- life approach and nonspecific binding to microsomes. Drug Metab. Dispos. (1999) 27(11):1350-1359.
  • RILEY RJ, MCGINNITY DF, AUSTIN RP: A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. (2005) 33(9):1304-1311.
  • GIBALDI M, PERRIER D: Pharmacokinetics. Marcel Dekker, Inc., New York, USA (1982).
  • CHIOU WL: New perspectives on the theory of permeability and resistance in the study of drug transport and absorption. J. Pharmacokinet. Biopharm. (1996) 24(4):433-442.
  • AVDEEF A: Physicochemical profiling (solubility, permeability and charge state). Curr. Top. Med. Chem. (2001) 1(4):277-351.
  • SABNIS S: Factors influencing the bioavailability of peroral formulations of drugs for dogs. Vet. Res. Commun. (1999) 23(7):425-447.
  • POUTON CW: Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. (2006) 29(3-4):278-287.
  • ZHOU H: Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J. Clin. Pharmacol. (2003) 43(3):211-227.
  • KRAMER SD, WUNDERLI-ALLENSPACH H: Physicochemical properties in pharmacokinetic lead optimization. Farmaco (2001) 56(1-2):145-148.
  • HORTER D, DRESSMAN JB: Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. (2001) 46(1-3):75-87.
  • DESESSO JM, JACOBSON CF: Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol. (2001) 39(3):209-228.
  • KARARLI TT: Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. (1995) 16(5):351-380.
  • HEBEL R, STROMBERG MW: Anatomy and Embryology of the Laboratory Rat. BioMed Verlag, Worthsee, Germany (1986).
  • SNYDER WS, COOK MJ, NASSET ES, KARHAUSEN LR, HOWELLS GP, TIPTON IH: Report of the Task Group on Reference Man. Wiley, New York, USA (1975).
  • ROWLAND M, TOZER TN: Clinical Pharmacokinetics Concepts and Application. Lippincott Williams & Wilkins, Philadelphia, USA (1995).
  • SHARGEL L, YU A: Applied Biopharmaceutics and Pharmacokinetics. Appleton and Lange, Stamford, New York, USA (1999).
  • WINNE D: Unstirred layer thickness in perfused rat jejunum in vivo. Experientia (1976) 32(10):1278-1279.
  • HAYTON WL: Rate-limiting barriers to intestinal drug absorption: a review. J. Pharmacokinet. Biopharm. (1980) 8(4):321-334.
  • STROCCHI A, CORAZZA G, FURNE J: Measurements of the jejunal unstirred layer in normal subjects and patients with celiac disease (1996).
  • CHIOU WL: Effect of ‘unstirred’ water layer in the intestine on the rate and extent of absorption after oral administration. Biopharm. Drug Dispos. (1994) 15(8):709-717.
  • KIMURA T, HIGAKI K: Gastrointestinal transit and drug absorption. Biol. Pharm. Bull. (2002) 25(2):149-164.
  • MARTINEZ M, AMIDON G, CLARKE L, JONES WW, MITRA A, RIVIERE J: Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. Adv. Drug Deliv. Rev. (2002) 54(6):825-850.
  • GARANERO G, RAMANATHAN S, AMIDON G: Gastrointestinal dissolution and absorption of drugs. In: Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability. Waterbeemd HVD, Lennernas H, Artursson P (Eds), Wiley-VCH, Zurich, Switzerland (2005):191-210.
  • LENNERNAS H, REGARDH CG: Regional gastrointestinal absorption of the β-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000. Pharm. Res. (1993) 10(1):130-135.
  • SOERGEL KH: Flow measurements of test meals and fasting contents in human small intestine. Proceedings of the International Symposium on Motility of the Gastrointestinal Tract. Thieme, Stuttgart, Germany (1971).
  • ENCK P, MERLIN V, ERCKENBRECHT JF, WIENBECK M: Stress effects on gastrointestinal transit in the rat. Gut (1989) 30(4):455-459.
  • ENCK P, WIENBECK M: Repeated noninvasive measurement of gastrointestinal transit in rats. Physiol. Behav. (1989) 46(4):633-637.
  • CHARMAN WN, PORTER CJ, MITHANI S, DRESSMAN JB: Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. (1997) 86(3):269-282.
  • HANANO M: Fat-soluble vitamins: Intestinal absorption. Nippon Rinsho (1993) 51(4):851-857.
  • KIRILENKO VN, GREGORIADIS G: Fat soluble vitamins in liposomes: studies on incorporation efficiency and bile salt induced vesicle disintegration. J. Drug Target (1993) 1(4):361-368.
  • CUMMINGS JH, MACFARLANE GT: Role of intestinal bacteria in nutrient metabolism. J. Parenter. Enteral. Nutr. (1997) 21(6):357-365.
  • BLAUT M, SCHOEFER L, BRAUNE A: Transformation of flavonoids by intestinal microorganisms. Int. J. Vitam. Nutr. Res. (2003) 73(2):79-87.
  • LICHTENSTEIN AH: Intestinal cholesterol metabolism. Ann. Med. (1990) 22(1):49-52.
  • BOWEY E, ADLERCREUTZ H, ROWLAND I: Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem. Toxicol. (2003) 41(5):631-636.
  • RUMNEY CJ, ROWLAND IR: In vivo and in vitro models of the human colonic flora. Crit. Rev. Food Sci. Nutr. (1992) 31(4):299-331.
  • TREVASKIS NL, PORTER CJ, CHARMAN WN: The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J. Pharmacol. Exp. Ther. (2006) 316(2):881-891.
  • TREVASKIS NL, PORTER CJ, CHARMAN WN: Bile increases intestinal lymphatic drug transport in the fasted rat. Pharm. Res. (2005) 22(11):1863-1870.
  • CHEEMA M, PALIN KJ, DAVIS SS: Lipid vehicles for intestinal lymphatic drug absorption. J. Pharm. Pharmacol. (1987) 39(1):55-56.
  • EDWARDS GA, PORTER CJ, CALIPH SM, KHOO SM, CHARMAN WN: Animal models for the study of intestinal lymphatic drug transport. Adv. Drug Deliv. Rev. (2001) 50(1-2):45-60.
  • LENNERNAS H: Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Pharm. Res. (1995) 12(11):1573-1582.
  • KARLSSON J, UNGELL A, GRASJO J, ARTURSSON P: Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. Eur. J. Pharm. Sci. (1999) 9(1):47-56.
  • HE YL, MURBY S, WARHURST G et al.: Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J. Pharm. Sci. (1998) 87(5):626-633.
  • AVDEEF A, TESTA B: Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. Cell Mol. Life Sci. (2002) 59(10):1681-1689.
  • LIPINSKI CA: Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods (2000) 44(1):235-249.
  • KUNTA JR, SINKO PJ: Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Metab. (2004) 5(1):109-124.
  • FRIEND DR: Drug delivery to the small intestine. Curr. Gastroenterol. Rep. (2004) 6(5):371-376.
  • PUTNAM WS, RAMANATHAN S, PAN L, TAKAHASHI LH, BENET LZ: Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J. Pharm. Sci. (2002) 91(12):2622-2635.
  • KATSURA T, INUI K: Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab. Pharmacokinet. (2003) 18(1):1-15.
  • OH DM, HAN HK, WILLIAMSON RM et al.: Improved intestinal transport of PD 158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters. J. Pharm. Sci. (2002) 91(12):2579-2587.
  • GLAESER H, BAILEY DG, DRESSER GK et al.: Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. (2007) 81(3):362-370.
  • DOHERTY MM, CHARMAN WN: The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet. (2002) 41(4):235-253.
  • BLEASBY K, CASTLE JC, ROBERTS CJ et al.: Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica (2006) 36(10-11):963-988.
  • ABEL S, BEAUMONT KC, CRESPI CL et al.: Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica (2001) 31(8-9):665-676.
  • EL ELA AA, HARTTER S, SCHMITT U, HIEMKE C, SPAHN-LANGGUTH H, LANGGUTH P: Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds –implications for pharmacokinetics of selected substrates. J. Pharm. Pharmacol. (2004) 56(8):967-975.
  • SALPHATI L, BENET LZ: Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology (1998) 56(6):308-313.
  • CHIOU WL, BARVE A: Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. (1998) 15(11):1792-1795.
  • CHIOU WL, MA C, CHUNG SM, WU TC, JEONG HY: Similarity in the linear and non-linear oral absorption of drugs between human and rat. Int. J. Clin. Pharmacol. Ther. (2000) 38(11):532-539.
  • LIPINSKI CA: Computational alerts for potential absorption problems: profiles of clinically tested drugs. In: Tools for Oral Absorption. Part Two. Predicting Human Absorption. In: AAPS Meeting. AAPS, Miami, USA (1995).
  • LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (2001) 46(1-3):3-26.
  • DARVAS F, KESERU G, PAPP A, DORMAN G, URGE L, KRAJCSI P: In silico and ex silico ADME approaches for drug discovery. Curr. Top. Med. Chem. (2002) 2(12):1287-1304.
  • PALM K, LUTHMAN K, UNGELL AL, STRANDLUND G, ARTURSSON P: Correlation of drug absorption with molecular surface properties. J. Pharm. Sci. (1996) 85(1):32-39.
  • PALM K, STENBERG P, LUTHMAN K, ARTURSSON P: Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. (1997) 14(5):568-571.
  • KELDER J, GROOTENHUIS PD, BAYADA DM, DELBRESSINE LP, PLOEMEN JP: Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. (1999) 16(10):1514-1519.
  • KUBINYI H: Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzneimittelforschung (1979) 29(8):1067-1080.
  • MARTINEZ MN, AMIDON GL: A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharm. (2002) 42(6):620-643.
  • KRAMER SF, FLYNN GL: Solubility of organic hydrochlorides. J. Pharm. Sci. (1972) 61(12):1896-1904.
  • CHOWHAN ZT: pH-solubility profiles or organic carboxylic acids and their salts. J. Pharm. Sci. (1978) 67(9):1257-1260.
  • LI S, HE H, PARTHIBAN LJ, YIN H, SERAJUDDIN AT: IV – IVC considerations in the development of immediate-release oral dosage form. J. Pharm. Sci. (2005) 94(7):1396-1417.
  • CHAUMEIL JC: Micronization: a method of improving the bioavailability of poorly soluble drugs. Methods Find. Exp. Clin. Pharmacol. (1998) 20(3):211-215.
  • HIROI T, CHOW T, IMAOKA S, FUNAE Y: Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab. Dispos. (2002) 30(9):970-976.
  • FRENNING G, STROMME M: Drug release modeled by dissolution, diffusion, and immobilization. Int. J. Pharm. (2003) 250(1):137-145.
  • HEALY MA: Theoretical model of gastrointestinal absorption of lead. J. Clin. Hosp. Pharm. (1984) 9(3):257-261.
  • BORM P, KLAESSIG FC, LANDRY TD et al.: Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. Toxicol. Sci. (2006) 90(1):23-32.
  • NYSTROM C, BISRAT M: Coulter Counter measurements of solubility and dissolution rate of sparingly soluble compounds using micellar solutions. J. Pharm. Pharmacol. (1986) 38(6):420-425.
  • NYSTROM C, MAZUR J, BARNETT MI, GLAZER M: Dissolution rate measurements of sparingly soluble compounds with the Coulter Counter model TAII. J. Pharm. Pharmacol. (1985) 37(4):217-221.
  • NELSON E: Solution rate of theophylline salts and effects from oral administration. J. Am. Pharm. Assoc. (Baltim.) (1957) 46(10):607-614.
  • NELSON E: Comparative dissolution rates of weak acids and their sodium salts. J. Am. Pharm. Assoc. (Baltim.) (1958) 47(4):297-299.
  • BERGE SM, BIGHLEY LD, MONKHOUSE DC: Pharmaceutical salts. J. Pharm. Sci. (1977) 66(1):1-19.
  • HENDRIKSEN BA, FELIX MV, BOLGER MB: The composite solubility versus pH profile and its role in intestinal absorption prediction. AAPS Pharm. Sci. (2003) 5(1):E4.
  • HUANG LF, TONG WQ: Impact of solid state properties on developability assessment of drug candidates. Adv. Drug Deliv. Rev. (2004) 56(3):321-334.
  • STRICKLEY RG: Solubilizing excipients in oral and injectable formulations. Pharm. Res. (2004) 21(2):201-230.
  • CHEN X, MORRIS KR, GRIESSER UJ, BYRN SR, STOWELL JG: Reactivity differences of indomethacin solid forms with ammonia gas. J. Am. Chem. Soc. (2002) 124(50):15012-15019.
  • NANG LS, COSNIER D, TERRIE G, MOLEYRE J: Consequence of solubility alteration by salt effect on dissolution enhancement and biological response of a solid dispersion of an experimental antianginal drug. Pharmacology (1977) 15(6):545-550.
  • PUDIPEDDI M, SERAJUDDIN AT: Trends in solubility of polymorphs. J. Pharm. Sci. (2005) 94(5):929-939.
  • SINGHAL D, CURATOLO W: Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev. (2004) 56(3):335-347.
  • MATSUDA Y, AKAZAWA R, TERAOKA R, OTSUKA M: Pharmaceutical evaluation of carbamazepine modifications: comparative study of photostability for carbamazepine polymorphs by using Fourier-transformed reflection-absorption infrared spectroscopy and calorimetric measurement. J. Pharm. Phamacol. (1993) 46:162-167.
  • COHEN MD, GREEN BS: Organic chemistry in the solid state. Chem. Br. (1973) 9:490-497.
  • DE VILLIERS MM, VAN DER WATT JG, LOTTER AP: Kinetic study of the solid-state photolytic degradation of two polymorphic forms of furosemide. Int. J. Pharm. (1992) 88:275-283.
  • EYJOLFSSON R: Enalapril maleate polymorphs: instability of form II in a tablet formulation. Pharmazie (2002) 57(5):347-348.
  • KAUSHAL AM, GUPTA P, BANSAL AK: Amorphous drug delivery systems: molecular aspects, design, and performance. Crit. Rev. Ther. Drug Carrier Syst. (2004) 21(3):133-193.
  • DOELKER E: Crystalline modifications and polymorphism changes during drug manufacture. Ann. Pharm. Fr. (2002) 60(3):161-176.
  • CRAIG DQ, ROYALL PG, KETT VL, HOPTON ML: The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. Int. J. Pharm. (1999) 179(2):179-207.
  • VAN GELDER J, SHAFIEE M, DE CLERCQ E et al.: Species-dependent and site-specific intestinal metabolism of ester prodrugs. Int. J. Pharm. (2000) 205(1-2):93-100.
  • VAN DE WATERBEEMD H, SMITH DA, BEAUMONT K, WALKER DK: Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. (2001) 44(9):1313-1333.
  • BEAUMONT K, WEBSTER R, GARDNER I, DACK K: Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab. (2003) 4(6):461-485.
  • SHIMPI S, CHAUHAN B, SHIMPI P: Cyclodextrins: application in different routes of drug administration. Acta Pharm. (2005) 55(2):139-156.
  • LOFTSSON T, MASSON M, SIGURDSSON HH: Cyclodextrins and drug permeability through semi-permeable cellophane membranes. Int. J. Pharm. (2002) 232(1-2):35-43.
  • IRIE T, UEKAMA K: Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. (1997) 86(2):147-162.
  • KAKEMI K, SEZAKI H, OGATA H, NADAI T: Absorption and excretion of drugs. XXXVI. Effect of Ca2+ on the absorption of tetracycline from the small intestine. (1). Chem. Pharm. Bull. (Tokyo) (1968) 16(11):2200-2205.
  • KAKEMI K, SEZAKI H, HAYASHI M, NADAI T: Absorption and excretion of drugs. XXXVII. Effect of Ca2+ on the absorption of tetracycline from the small intestine. (2). Chem. Pharm. Bull. (Tokyo) (1968) 16(11):2206-2212.
  • GUGLER R, ALLGAYER H: Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin. Pharmacokinet. (1990) 18(3):210-219.
  • JUNG H, PEREGRINA AA, RODRIGUEZ JM, MORENO-ESPARZA R: The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm. Drug Dispos. (1997) 18(5):459-463.
  • SMITH DA: Physicochemical properties in drug metabolism and pharmacokinetics. In: Computer-Assisted Lead Finding and Optimization. Current Tools for Medicinal Chemistry. Waterbeemd HVD, Testa B, Folkers G (Eds), Wiley-VCH, Weinheim, Germany (1997):267-276.
  • POND SM, TOZER TN: First-pass elimination Basic concepts and clinical consequences. Clin. Pharmacokinet. (1984) 9(1):1-25.
  • BOYES RN, SCOTT DB, JEBSON PJ, GODMAN MJ, JULIAN DG: Pharmacokinetics of lidocaine in man. Clin. Pharmacol. Ther. (1971) 12(1):105-116.
  • BENOWITZ NL, MEISTER W: Clinical pharmacokinetics of lignocaine. Clin. Pharmacokinet. (1978) 3(3):177-201.
  • BRUNTON L, LAZO J, PARKER K: Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw Hill, New York, USA (2006).
  • PAINE MF, SHEN DD, KUNZE KL et al.: First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. (1996) 60(1):14-24.
  • LEHLE K, KIRCHNER G, SEWING KF, RUPPRECHT L, MERK J, PREUNER JG: Intestinal metabolism of cyclosporine A in human heart transplant recipients. Transplant. Proc. (1998) 30(8):4044.
  • GONZALEZ FJ: The molecular biology of cytochrome P450s. Pharmacol. Rev. (1988) 40(4):243-288.
  • NELSON DR, KOYMANS L, KAMATAKI T et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics (1996) 6(1):1-42.
  • PETERS W, KREMERS P: Cytochromes P-450 in the intestinal mucosa of man. Biochem. Pharmacol. (1989) 38(9):1535-1538.
  • SHIMADA T, YAMAZAKI H, MIMURA M, INUI Y, GUENGERICH FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. (1994) 270(1):414-423.
  • SPATZENEGGER M, JAEGER W: Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab. Rev. (1995) 27(3):397-417.
  • MCGINNITY DF, PARKER AJ, SOARS M, RILEY RJ: Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab. Dispos. (2000) 28(11):1327-1334.
  • DAI D, ZELDIN DC, BLAISDELL JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 11(7):597-607.
  • DESAI PB, DUAN JZ, ZHU YW, KOUZI S: Human liver microsomal metabolism of paclitaxel and drug interactions. Eur. J. Drug Metab. Pharmacokinet. (1998) 23(3):417-424.
  • O DCJ, GRIME K, COURTNEY P, SLEE D, RILEY RJ: The development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a Drug Discovery Setting. Drug Metab. Dispos. (2007) 35(3):381-385.
  • CASABAR RCT, WALLACE AD, HODGSON E, ROSE RL: Metabolism of endosulfan-α by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4. Drug Metab. Dispos. (2006) 34(10):1779-1785.
  • TURPEINEN M, RAUNIO H, PELKONEN O: The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr. Drug Metab. (2006) 7(7):705-714.
  • MIRGHANI RA, SAYI J, AKLILLU E et al.: CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet. Genom. (2006) 16(9):637-645.
  • SMITH DA, ABEL SM, HYLAND R, JONES BC: Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica (1998) 28(12):1095-1128.
  • IKEYA K, JAISWAL AK, OWENS RA, JONES JE, NEBERT DW, KIMURA S: Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol. Endocrinol. (1989) 3(9):1399-1408.
  • SHIMADA T, MARTIN MV, PRUESS-SCHWARTZ D, MARNETT LJ, GUENGERICH FP: Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7, 8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res. (1989) 49(22):6304-6312.
  • IBA MM, STORCH A, GHOSAL A, BENNETT S, REUHL KR, LOWNDES HE: Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum. Arch. Toxicol. (2003) 77(10):547-554.
  • GUENGERICH FP: Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem. Biol. Interact. (1997) 106(3):161-182.
  • LINDELL M, LANG M, LENNERNAS H: Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver. Eur. J. Drug Metab. Pharmacokinet. (2003) 28(1):41-48.
  • PAINE MF, HART HL, LUDINGTON SS, HAINING RL, RETTIE AE, ZELDIN DC: The human intestinal cytochrome P450 “pie”. Drug Metab. Dispos. (2006) 34(5):880-886.
  • SHIMADA T, YAMAZAKI H, MIMURA M et al.: Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. (1996) 24(5):515-522.
  • HAKKOLA J, PASANEN M, HUKKANEN J et al.: Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. (1996) 51(4):403-411.
  • HAKKOLA J, RAUNIO H, PURKUNEN R et al.: Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol. (1996) 52(2):379-383.
  • SMITH GB, HARPER PA, WONG JM et al.: Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol. Biomarkers Prev. (2001) 10(8):839-853.
  • FONTANA RJ, LOWN KS, PAINE MF et al.: Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology. (1999) 117(1):89-98.
  • SESARDIC D, BOOBIS AR, MURRAY BP et al.: Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. (1990) 29(6):651-663.
  • GOLDSTEIN JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J Clin. Pharmacol. (2001) 52(4):349-355.
  • LAPPLE F, VON RICHTER O, FROMM MF et al.: Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics (2003) 13(9):565-575.
  • TRELUYER JM, GUERET G, CHERON G, SONNIER M, CRESTEIL T: Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics (1997) 7(6):441-452.
  • MODE A, AHLGREN R, LAHUNA O, GUSTAFSSON JA: Gender differences in rat hepatic CYP2C gene expression – regulation by growth hormone. Growth Horm. IGF Res. (1998) 8(Suppl B):61-67.
  • RICH KJ, BOOBIS AR: Expression and inducibility of P450 enzymes during liver ontogeny. Microsc. Res. Tech. (1997) 39(5):424-435.
  • OHHIRA S, ENOMOTO M, MATSUI H: In vitro metabolism of tributyltin and triphenyltin by human cytochrome P-450 isoforms. Toxicology (2006) 228(2-3):171-177.
  • MUGFORD CA, KEDDERIS GL: Sex-dependent metabolism of xenobiotics. Drug Metab. Rev. (1998) 30(3):441-498.
  • ZANGER UM, RAIMUNDO S, EICHELBAUM M: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369(1):23-37.
  • MURALIDHARAN G, HAWES EM, MCKAY G, KORCHINSKI ED, MIDHA KK: Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Eur. J. Clin. Pharmacol. (1991) 41(5):471-474.
  • MURALIDHARAN G, HAWES EM, MCKAY G, MIDHA KK: Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Xenobiotica (1991) 21(11):1441-1450.
  • WRIGHTON SA, BRIAN WR, SARI MA et al.: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. (1990) 38(2):207-213.
  • KUEHL P, ZHANG J, LIN Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. (2001) 27(4):383-391.
  • PAINE MF, KHALIGHI M, FISHER JM et al.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. (1997) 283(3):1552-1562.
  • SMIT P, VAN SCHAIK RH, VAN DER WERF M et al.: A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J. Clin. Endocrinol. Metab. (2005) 90(9):5313-5316.
  • GELLNER K, EISELT R, HUSTERT E et al.: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics (2001) 11(2):111-121.
  • DOMANSKI TL, FINTA C, HALPERT JR, ZAPHIROPOULOS PG: cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. (2001) 59(2):386-392.
  • CHEN M, MA L, DRUSANO GL, BERTINO JS Jr, NAFZIGER AN: Sex differences in CYP3A activity using intravenous and oral midazolam. Clin. Pharmacol. Ther. (2006) 80(5):531-538.
  • ROBERTSON GR, FARRELL GC, LIDDLE C: Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. Biochem. Biophys. Res. Commun. (1998) 242(1):57-60.
  • YAMAZOE Y, MURAYAMA N, SHIMADA M et al.: A sex-specific form of cytochrome P-450 catalyzing propoxycoumarin O-depropylation and its identity with testosterone 6 β-hydroxylase in untreated rat livers: reconstitution of the activity with microsomal lipids. J. Biochem. (Tokyo) (1988) 104(5):785-790.
  • MATSUBARA T, KIM HJ, MIYATA M, SHIMADA M, NAGATA K, YAMAZOE Y: Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J. Pharmacol. Exp. Ther. (2004) 309(3):1282-1290.
  • SMITH DA: Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab. Rev. (1991) 23(3-4):355-373.
  • WARRINGTON JS, VON MOLTKE LL, SHADER RI, GREENBLATT DJ: In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11. Drug Metab. Dispos. (2002) 30(6):655-657.
  • GHOSAL A, SATOH H, THOMAS PE, BUSH E, MOORE D: Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab. Dispos. (1996) 24(9):940-947.
  • LU C, LI AP: Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague–Dawley rat, minipig, and beagle dog. Chem. Biol. Interact. (2001) 134(3):271-281.
  • MACKENZIE PI, OWENS IS, BURCHELL B et al.: The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics (1997) 7(4):255-269.
  • WILLIAMS JA, HYLAND R, JONES BC et al.: Drug–drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. (2004) 32(11):1201-1208.
  • KING CD, RIOS GR, GREEN MD, TEPHLY TR: UDP-glucuronosyltransferases. Curr. Drug Metab. (2000) 1(2):143-161.
  • SHELBY MK, CHERRINGTON NJ, VANSELL NR, KLAASSEN CD: Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab. Dispos. (2003) 31(3):326-333.
  • MARTIN IJ, LEWIS RJ, BERNSTEIN MA et al.: Which hydroxy? Evidence for species differences in the regioselectivity of glucuronidation in rat, dog, and human in vitro systems and dog in vivo. Drug Metab. Dispos. (2006) 34(9):1502-1507.
  • BOERSMA MG, VAN DER WOUDE H, BOGAARDS J et al.: Regioselectivity of Phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem. Res. Toxicol. (2002) 15(5):662-670.
  • SAUER JM, RING BJ, WITCHER JW: Clinical pharmacokinetics of atomoxetine. Clin. Pharmacokinet. (2005) 44(6):571-590.
  • MATTIUZ EL, PONSLER GD, BARBUCH RJ et al.: Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. Drug Metab. Dispos. (2003) 31(1):88-97.
  • LIN JH, CHIBA M, BALANI SK et al.: Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. (1996) 24(10):1111-1120.
  • CHIBA M, HENSLEIGH M, NISHIME JA, BALANI SK, LIN JH: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. (1996) 24(3):307-314.
  • YEH KC, STONE JA, CARIDES AD, ROLAN P, WOOLF E, JU WD: Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. J. Pharm. Sci. (1999) 88(5):568-573.
  • SMITH DA, VAN DE WATERBEEMD H, WALKER DK: Pharmacokinetics and Metabolism in Drug Design. Wiley-VCH, Amsterdam, The Netherlands (2006).
  • RAEVSKY OA: Physicochemical descriptors in property-based drug design. Mini. Rev. Med. Chem. (2004) 4(10):1041-1052.
  • STONER CL, CLETON A, JOHNSON K et al.: Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. Int. J. Pharm. (2004) 269(1):241-249.
  • BOOBIS A, GUNDERT-REMY U, KREMERS P, MACHERAS P, PELKONEN O: In silico prediction of ADME and pharmacokinetics – Report of an expert meeting organised by COST B15. Eur. J. Pharm. Sci. (2002) 17(4-5):183-193.
  • GOMBAR VK, SILVER IS, ZHAO Z: Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability. Curr. Top. Med. Chem. (2003) 3(11):1205-1225.
  • VAN DE WATERBEEMD H: High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr. Opin. Drug Discov. Dev. (2002) 5(1):33-43.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.